Skip to main content
SpringerLink
Log in

Therapies for Delay or Prevention of Type 2 Diabetes

  • Chapter
Type 2 Diabetes Mellitus

Part of the book series: Contemporary Endocrinology ((COE))

Summary

As the epidemic of type 2 diabetes continues to grow, efforts to define effective diabetes prevention strategies are gaining momentum. Although lifestyle interventions have consistently been shown to reduce diabetes incidence, difficulties with long-term adherence and contraindications owing to concomitant morbidity associated with diabetes make pharmacological prevention strategies an attractive option. Oral antidiabetic agents, antiobesity agents, lipid lowering drugs, and antihypertensive medications have all been implicated in diabetes prevention. However, few studies have provided sufficient follow up to determine if noted reductions in diabetes incidence associated with the agents represent prevention or delay of the disease. Additionally, whether reducing diabetes incidence will subsequently translate to lasting benefits in morbidity and mortality remains unclear.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047–1053.

    Article  PubMed  Google Scholar 

  2. Hogan P, Dall T, Nikolov P; American Diabetes Association.Economic costs of diabetes in the US in 2002. Diabetes Care 2003;26:917–932.

    Article  PubMed  Google Scholar 

  3. U.K.Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 yr’ therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249–1258.

    Google Scholar 

  4. The DECODE Study Group, European Diabetes Epidemiology Group.Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003;26:688–696.

    Google Scholar 

  5. Coutinho M, Gerstein HC, Wang Y, Yusuf S.The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 yr. Diabetes Care 1999;22:233–240.

    Article  PubMed  CAS  Google Scholar 

  6. Gerstein HC.Glucose: a continuous risk factor for cardiovascular disease. Diabet Med 1997;14 Suppl 3:S25–31.

    Google Scholar 

  7. Pan XR, Li GW, Hu YH, et al.Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537–544.

    Article  PubMed  CAS  Google Scholar 

  8. Tuomilehto J, Lindstrom J, Eriksson JG, et al.Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–1350.

    Article  PubMed  CAS  Google Scholar 

  9. Knowler WC, Barrett-Connor E, Fowler SE, et al.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403.

    Article  PubMed  CAS  Google Scholar 

  10. Fontbonne A, Charles MA, Juhan-Vague I, et al.The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care 1996;19:920–926.

    Article  PubMed  CAS  Google Scholar 

  11. Ratner R, Goldberg R, Haffner S, et al.Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 2005;28:888–894.

    Article  PubMed  Google Scholar 

  12. Sartor G, Schersten B, Carlstrom S, Melander A, Norden A, Persson G.Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 1980;29:41–49.

    Article  PubMed  CAS  Google Scholar 

  13. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group.Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072–2077.

    Article  PubMed  CAS  Google Scholar 

  14. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group.Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486–494.

    Article  PubMed  CAS  Google Scholar 

  15. Buchanan TA, Xiang AH, Peters RK, et al.Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002;51:2796–2803.

    Article  PubMed  CAS  Google Scholar 

  16. Knowler WC, Hamman RF, Edelstein SL, et al.Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005;54:1150–1156.

    Article  PubMed  Google Scholar 

  17. Gerstein HC, Yusuf S, Bosch J, et al.Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096–1105.

    Article  PubMed  CAS  Google Scholar 

  18. Nissen SE, Wolski K.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457–71.

    Article  PubMed  Google Scholar 

  19. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L.XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155–161.

    Article  PubMed  CAS  Google Scholar 

  20. McFarlane SI, Banerji M, Sowers JR.Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001;86:713–718.

    Article  PubMed  CAS  Google Scholar 

  21. Rovellini A, Sommariva D, Branchi A, et al.Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia. Pharmacol Res 1992;25:237–245.

    Article  PubMed  CAS  Google Scholar 

  22. Jones IR, Swai A, Taylor R, Miller M, Laker MF, Alberti KG.Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM. Diabetes Care 1990;13:855–863.

    Article  PubMed  CAS  Google Scholar 

  23. BIP Study Group.Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21–27.

    Google Scholar 

  24. Tenenbaum A, Motro M, Fisman EZ, et al.Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2004;109:2197–2202.

    Article  PubMed  CAS  Google Scholar 

  25. Rubins HB, Robins SJ, Collins D, et al.Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410–418.

    Article  PubMed  CAS  Google Scholar 

  26. Robins SJ, Rubins HB, Faas FH, et al.Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003;26:1513–1517.

    Article  PubMed  CAS  Google Scholar 

  27. Shepherd J, Cobbe SM, Ford I, et al.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301–1307.

    Article  PubMed  CAS  Google Scholar 

  28. Freeman DJ, Norrie J, Sattar N, et al.Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357–362.

    PubMed  CAS  Google Scholar 

  29. Keech A, Colquhoun D, Best J, et al.Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003;26:2713–2721.

    Article  PubMed  CAS  Google Scholar 

  30. Sever PS, Dahlof B, Poulter NR, et al.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149–1158.

    Article  PubMed  CAS  Google Scholar 

  31. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart protection study collaborative group.MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005–2016.

    Article  PubMed  Google Scholar 

  32. Padwal R, Majumdar SR, Johnson JA, Varney J, McAlister FA.A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 2005;28:736–744.

    Article  PubMed  Google Scholar 

  33. Padwal R, Mamdani M, Alter DA, et al.Antihypertensive therapy and incidence of type 2 diabetes in an elderly cohort. Diabetes Care 2004;27:2458–2463.

    Article  PubMed  Google Scholar 

  34. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL.Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000;342:905–912.

    Article  PubMed  CAS  Google Scholar 

  35. Taylor EN, Hu FB, Curhan GC.Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 2006;29: 1065–1070.

    Google Scholar 

  36. Brown MJ, Palmer CR, Castaigne A, et al.Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366–372.

    Article  PubMed  CAS  Google Scholar 

  37. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al.A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805–2816.

    Article  PubMed  CAS  Google Scholar 

  38. Hansson L, Lindholm LH, Ekbom T, et al.Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751–1756.

    Article  PubMed  CAS  Google Scholar 

  39. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981–2997.

    Google Scholar 

  40. Dahlof B, Sever PS, Poulter NR, et al.Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895–906.

    Article  PubMed  Google Scholar 

  41. Hansson L, Lindholm LH, Niskanen L, et al.Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611–616.

    Article  PubMed  CAS  Google Scholar 

  42. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G.Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145–153.

    Article  PubMed  CAS  Google Scholar 

  43. Yusuf S, Gerstein H, Hoogwerf B, et al.Ramipril and the development of diabetes. JAMA 2001;286:1882–1885.

    Article  PubMed  CAS  Google Scholar 

  44. Bosch J, Yusuf S, Gerstein HC, et al.Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355:1551–1562.

    Article  PubMed  Google Scholar 

  45. Dahlof B, Devereux RB, Kjeldsen SE, et al.Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–1003.

    Article  PubMed  CAS  Google Scholar 

  46. Lithell H, Hansson L, Skoog I, et al.The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875–886.

    Article  PubMed  CAS  Google Scholar 

  47. Pfeffer MA, Swedberg K, Granger CB, et al.Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759–766.

    Article  PubMed  CAS  Google Scholar 

  48. Julius S, Kjeldsen SE, Weber M, et al.Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022–2031.

    Article  PubMed  CAS  Google Scholar 

  49. Diabetes Prevention Program Research Group.Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program.[comment]. Diabetes Care 2003;26:977–980.

    Google Scholar 

Download references

Authors
  1. Mary Angelyn Bethel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Duke University Medical Center Durham, NC, USA

    Mark N. Feinglos MD, CM  & M. Angelyn Bethel MD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Bethel, M.A. (2008). Therapies for Delay or Prevention of Type 2 Diabetes. In: Feinglos, M.N., Bethel, M.A. (eds) Type 2 Diabetes Mellitus. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-60327-043-4_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-043-4_6

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-794-5

  • Online ISBN: 978-1-60327-043-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation